$MMI

Marcus & Millichap (MMI) Q2 2026 Earnings Call Transcript

Marcus & Millichap (MMI) reported Q2 2026 revenue of $203M, up 18% YoY, with all segments growing. Net income was $4M ($0.10 per share), reversing a prior-year loss. Brokerage and financing revenues increased, with transaction volumes up 11% and 17% YoY, respectively. Management highlighted growth in larger transactions and financing, but noted interest rate volatility as a challenge.

Original reporting
Published Aug 19, 2026, 6:29 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Marcus & Millichap (MMI) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$MMIBullishMed
01

Why it matters

Earnings beat and dividend may trigger buying pressure, while cost growth and rate volatility remain risks.

02

Market read

First earnings report of the quarter with new financial metrics, making it a primary source of trading information.

03

What to watch

Potential slowdown in loan origination if treasury yields stay elevated.

Relevance 8/10Novelty 8/10Timing: Q2 2026 earnings release

Background

Marcus & Millichap reported Q2 2026 results, highlighting revenue growth across all segments and a return to profitability.

Company-level read

Ticker impact

$MMIBullishHigh confidence
Context

Q2 2026 earnings released with revenue up 18% YoY, net income turning positive and dividend declared.

Expected impact

Potential short‑term price rally on earnings beat and dividend announcement.

Evidence & confidence

First‑time profit, dividend, and share repurchases signal improved fundamentals and may attract income‑focused buyers.

Market effects

Strong results may lift the commercial real‑estate brokerage sector.

Positive for U.S. real‑estate services and related REITs.

Limited to U.S. markets; no direct global macro impact.

Counterpoint

Higher SG&A and interest‑rate volatility could pressure margins if rates rise further.

Key entities

  • Hessam Nadji

    CEO of Marcus & Millichap, provided guidance on growth strategy.

  • Steve DeGennaro

    CFO, discussed SG&A outlook and tax expense expectations.

Related articles

$MMIMedAI 8/10

Marcus & Millichap (MMI) Q2 2026 Earnings Call Transcript

Marcus & Millichap (MMI) reported Q2 2026 revenue of $203 million, up 18% from $172 million, driven by higher brokerage, private client, and larger transaction activity. Brokerage revenue rose 18% to $167 million; financing revenue rose 15% to $30 million. Net income was $4 million ($0.10/share) versus a prior-year net loss. Adjusted EBITDA improved to $12 million. The company declared a $0.25 dividend and repurchased shares.

$MMIMed

Marcus & Millichap Q2 Earnings Call Highlights

Marcus & Millichap (NYSE: MMI) reported Q2 financing revenue up 15% to $30 million, with transaction count up 17% to 480 and financing dollar volume up 5% to $4 billion. For the first half, financing revenue rose 29% to $57 million. Operating expenses rose to $201 million. Cash equivalents and marketable securities were $345 million. The board declared a $0.25 semiannual dividend and authorized further share repurchases.

$MMIMed

Marcus & Millichap, Inc. (MMI): Results of Operations and Financial Condition

Marcus & Millichap, Inc. (MMI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 er-q226earningsrelease.htm EX-99.1 Document MARCUS & MILLICHAP, INC. REPORTS PRELIMINARY RESULTS FOR SECOND QUARTER 2026 Revenue Grew 17.8% Compared to Second Quarter 2025 Net Income of $0.10 Per Diluted Share for Second Quarter 2026 CALABASAS, Calif., August 6, 2026 --

$MMIMed

Update on MMI and Further Investment

Crystal Amber Fund Limited said it invested a further $8.2 million in Morphic Medical Inc (MMI) since Feb 16, 2026, in three tranches at $0.48 per share, with the latest on July 31, 2026. The fund now holds 435,992,719 MMI shares (~97.9%). MMI reported FDA study pause removed, sites up to 40, US enrolment by early 2028, and Germany NUB status.